Technical Analysis for ADMS - Adamas Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
ADMS closed down 2.63 percent on Thursday, June 21, 2018, on 82 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
|See historical ADMS trend table...|
|Date||Alert Name||Type||% Chg|
|Jun 21||Lower Bollinger Band Walk||Weakness||0.00%|
|Jun 21||Inside Day||Range Contraction||0.00%|
|Jun 21||Oversold Stochastic||Weakness||0.00%|
|Jun 20||Lower Bollinger Band Walk||Weakness||-2.63%|
|Jun 20||Lower Bollinger Band Touch||Weakness||-2.63%|
|Jun 20||Oversold Stochastic||Weakness||-2.63%|
|Jun 19||Below Lower BB||Weakness||0.91%|
|Jun 19||Down 3 Days in a Row||Weakness||0.91%|
|Jun 19||Lower Bollinger Band Touch||Weakness||0.91%|
|Jun 19||Oversold Stochastic||Weakness||0.91%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Adamas Pharmaceuticals, Inc. focuses on the development and commercialization of therapeutics for chronic disorders of the central nervous systems (CNS) in the United States. The company is developing its lead product candidate, ADS-5102 that has completed a Phase 2/3 clinical study for levodopa induced dyskinesia, a complication of Parkinson's disease; and as a treatment for chronic behavioral symptoms associated with traumatic brain injury. It is also developing ADS-8800 and ADS-9000 series of products for use in a range of CNS indications; ADS-8704, a fixed-dose combination of memantine and donepezil for the treatment of moderate to severe dementia related to alzheimer's disease; and ADS-8902, a triple combination antiviral drug therapy for influenza. In addition, the company develops memantine-based therapeutics portfolio includes Namenda XR and MDX-8704, which are used in the treatment of dementia associated with moderate to severe alzheimer's disease. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ADMS news...
|52 Week High||44.0|
|52 Week Low||13.5|
|200-Day Moving Average||28.4136|
|50-Day Moving Average||28.6038|
|20-Day Moving Average||27.5785|
|10-Day Moving Average||26.717|
|Average True Range||1.1313|
|Chandelier Exit (Long, 3 ATRs )||27.5661|
|Chandelier Exit (Short, 3 ATRs )||28.4239|
|Upper Bollinger Band||29.9195|
|Lower Bollinger Band||25.2375|
|Percent B (%b)||0.06|
|MACD Signal Line||-0.6522|
|Market Cap||574.11 Million|
|Num Shares||22.5 Million|
|Price-to-Earnings (P/E) Ratio||-8.53|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||27.06|
|Resistance 3 (R3)||27.20||26.82||26.80|
|Resistance 2 (R2)||26.82||26.42||26.75||26.71|
|Resistance 1 (R1)||26.16||26.18||25.97||26.02||26.63|
|Support 1 (S1)||25.12||25.38||24.93||24.98||24.37|
|Support 2 (S2)||24.74||25.14||24.67||24.29|
|Support 3 (S3)||24.08||24.74||24.20|
|Support 4 (S4)||23.94|